G359

Special single agent or multi-agent therapy – chemotherapy and/or biologic agent(s) with major toxicity that require frequent monitoring and prolonged administration periods and may require immediate intervention by the physician .

Fee

ComponentValue
Provider fee$105.15
Schedule and sources
Fee edition
October 1, 2026
Record effective
2025-04-01
Schedule edition
July 22, 2026; effective July 1, 2026
Official files

PDF page 471 / J57

Special single agent or multi-agent therapy – chemotherapy and/or biologic agent(s) with major toxicity that require frequent monitoring and prolonged administration periods and may require immediate intervention by the physician . 105.15
Passages mentioning G359

PDF page 471 / J57

Chemotherapy and patient assessment provided by a physician includes all patient
          assessments by any physician for a 24 hour period following treatment administration.
          Note:
          1.G381, G345 and G359 are only eligible for payment with respect to the following classes of
            biologic agents:
             a.monoclonal antibodies; and
             b.cytokines.
          2.G381, G345, G359, G075 and G390 include venipuncture, establishment of any vascular
            access line and administration of agent(s).
     [Commentary:
     Examples that are not considered biologic agents for payment purposes are blood products,
     insulin, and immunizing agents.]
+ G381 Standard chemotherapy - agents with minor toxicity that
          require physician monitoring, including any additional
          standard chemotherapy other than the initial agent ...........         54.50
          [Commentary:
          Examples of standard chemotherapy agents include cyclophosphamide, methotrexate,
          fluorouracil, leucovorin, and zoledronic acid.]
   G345 Complex single agent or multi-agent therapy – chemotherapy
          and/or biologic agent(s) that can cause vesicant damage,
          infusion reactions, cardiac, neurologic, marrow or renal
          toxicities that may require immediate intervention by the
          physician ............................................................................    75.00
          [Commentary:
          Examples of complex single agents include rituxamib, bevacizumab, trastuzumab,
          anthracyclines, bortezomib, taxanes, cisplatin, and etoposide fludarabine.]
   G359 Special single agent or multi-agent therapy – chemotherapy
          and/or biologic agent(s) with major toxicity that require
          frequent monitoring and prolonged administration periods
          and may require immediate intervention by the physician .                                105.15
          [Commentary:
          Examples of special agent therapy include high-dose methotrexate with folinic acid rescue,
          methotrexate given in a dose of greater than 1 g/m2, high dose cisplatin greater than 75 mg/m2
          given concurrently with hydration and osmotic diuresis, high dose cystosine, arabinoside
          (greater than 2 g/m2), high dose cyclophosphamide (greater than 1 g/m2), ifosfamide with
          MESNA protection, combination of biologic agents with complex chemotherapy, bispecific
          antibody.]
Fee master record

Master, record 2071. Record Layout PDF, page 1.

G35920250401999999990000105150000000000000000000000000000000000000000000000

Auxiliary master fields are preserved as raw scaled values. The linked layout calls them zero-filled, but this edition contains non-zero values. They are not presented as final dollar fees or PDF units.

FieldRaw / scale 10,000
provider00001051500 / 105.15
assistant00000000000 / 0
specialist00000000000 / 0
anaesthetist00000000000 / 0
non anaesthetist00000000000 / 0
Explanation

AI-generated. Unreviewed.

Special single agent or multi-agent therapy using chemotherapy and/or biologic agents with major toxicity that require frequent monitoring and prolonged administration periods and may require immediate intervention by the physician, listed under Chemotherapy.

Watch out for

Only eligible for payment for certain classes of biologic agents, including monoclonal antibodies; the source text is cut off after this point.

Sources and updates
Fee master effective October 1, 2026Schedule effective July 1, 2026Source versions and changes
Preparing offline search…